TITLE

Texture analysis on MR images helps predicting non-response to NAC in breast cancer

AUTHOR(S)
Michoux, N.; Van den Broeck, S.; Lacoste, L.; Fellah, L.; Galant, C.; Berlière, M.; Leconte, I.
PUB. DATE
August 2015
SOURCE
BMC Cancer;Aug2015, Vol. 15 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: To assess the performance of a predictive model of non-response to neoadjuvant chemotherapy (NAC) in patients with breast cancer based on texture, kinetic, and BI-RADS parameters measured from dynamic MRI. Methods: Sixty-nine patients with invasive ductal carcinoma of the breast who underwent pre-treatment MRI were studied. Morphological parameters and biological markers were measured. Pathological complete response was defined as the absence of invasive and in situ cancer in breast and nodes. Pathological non-responders, partial and complete responders were identified. Dynamic imaging was performed at 1.5 T with a 3D axial T1W GRE fat-suppressed sequence. Visual texture, kinetic and BI-RADS parameters were measured in each lesion. ROC analysis and leave-one-out cross-validation were used to assess the performance of individual parameters, then the performance of multi-parametric models in predicting non-response to NAC. Results: A model based on four pre-NAC parameters (inverse difference moment, GLN, LRHGE, wash-in) and k-means clustering as statistical classifier identified non-responders with 84% sensitivity. BI-RADS mass/non-mass enhancement, biological markers and histological grade did not contribute significantly to the prediction. Conclusion: Pre-NAC texture and kinetic parameters help predicting non-benefit to NAC. Further testing including larger groups of patients with different tumor subtypes is needed to improve the generalization properties and validate the performance of the predictive model.
ACCESSION #
109283269

 

Related Articles

  • Newer Therapies for the Treatment of Metastatic Breast Cancer: a Clinical Update. MOHAN, ANJANA; PONNUSANKAR, S. // Indian Journal of Pharmaceutical Sciences;May/Jun2013, Vol. 75 Issue 3, p251 

    Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence rates have increased since 1980, slowed in 1990, the rate of increase have leveled off since 2001. In spite of the advances in the early detection, treatment, surgery and...

  • Newer Therapies for the Treatment of Metastatic Breast Cancer: a Clinical Update. MOHAN, ANJANA; PONNUSANKAR, S. // Indian Journal of Pharmaceutical Sciences;May/Jun2013, Vol. 75 Issue 3, p251 

    Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence rates have increased since 1980, slowed in 1990, the rate of increase have leveled off since 2001. In spite of the advances in the early detection, treatment, surgery and...

  • "Ruptured" malignant phyllodes tumor of the breast: a case report. Ditsatham, Chagkrit; Somwangprasert, Areewan; Watcharachan, Kirati; Phanchaporn; Wongmaneerung // International Medical Case Reports Journal;Feb2016, Vol. 9, p35 

    Phyllodes tumor or cystosarcoma phyllodes is a rare disease and is usually seen in middle-aged patients. Ruptured phyllodes tumor is a very rare condition. Our study reports patient presentation, diagnosis method, and treatment of an unusual case. A 58-year-old premenopausal female was diagnosed...

  • MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy Jones, Ella F.; Sinha, Sumedha P.; Newitt, David C.; Klifa, Catherine; Kornak, John; Park, Catherine C.; Hylton, Nola M. // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Rationale and Objectives: Normal-appearing stromal tissues surrounding breast tumors can harbor abnormalities that lead to increased risk of local recurrence. The objective of this study was to develop a new imaging methodology to characterize the signal patterns of stromal tissue and to...

  • Lessons Learned. WRIGHT, BETH BRADFIELD // Marketing Health Services;Spring2013, Vol. 33 Issue 2, p10 

    In this article, the author shares her health care experience and discusses the lessons learned during her stage II breast cancer chemotherapy. She states that she was diagnosed with stage II breast cancer in the year 2012 and after surgery three additional cancer sites were found in the same...

  • Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.  // BMC Research Notes;2012, Vol. 5 Issue 1, p162 

    The article presents an observational study, that investigates clinical features, treatment and prognosis associated with Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer (MBC), in Morocco. HER2 refers to the human epidermal growth factor receptor....

  • Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence. Piva, Roberta; Ticconi, Flavia; Ceriani, Valentina; Scalorbi, Federica; Fiz, Francesco; Capitanio, Selene; Bauckneht, Matteo; Cittadini, Giuseppe; Sambuceti, Gianmario; Morbelli, Silvia // Breast Cancer: Targets & Therapy;Jul2017, Vol. 9, p461 

    In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful...

  • Initiating treatment quickly after a breast-cancer diagnosis can significantly improve survival.  // Women's Health Advisor;Mar2013, Vol. 17 Issue 3, p2 

    The article focuses on a research which states that initiation of the treatment after the diagnosis of breast cancer may increase the survival chances of patients.

  • Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Şendur, Mehmet; Aksoy, Sercan; Yaman, Şebnem; Arık, Zafer; Özdemir, Nuriye; Zengin, Nurullah; Altundağ, Kadri // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2601 

    Bisphosphonates are the most commonly used agents in the treatment of osteoporosis, and bisphosphonate therapy reduces the risk of skeletally related complications in patients with bone metastases due to malignancy. However, the effect of oral alendronate treatment on clinical and pathological...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics